Company Filing History:
2 out of 1,119 
2 out of 2,620 
Years Active: 2022-2024
Title: Innovations by Kreg A. Zimmern in Bioprocessing Technology
Introduction
Kreg A. Zimmern, based in San Antonio, TX, is a notable inventor recognized for his contributions to the field of bioprocessing technology. With two patents to his name, he has made significant advancements in T cell processing and manufacturing, which play a crucial role in cancer treatment through CAR T cell therapies.
Latest Patents
Zimmern's latest patents focus on a beads-free bioprocessor designed as an automated and cost-effective platform for T cell processing and manufacturing. T cells are essential in CAR T cell therapies for cancer treatment, yet their large-scale production in clinically relevant quantities poses a challenge. His 3D bioprocessor offers a scalable, beads-free, and user-friendly solution to enhance the accessibility and viability of CAR T cell therapy in cancer immunotherapy. Beyond CAR T cell applications, this innovative platform technology has potential uses in various areas, including cancer cell isolation.
Career Highlights
Throughout his career, Kreg A. Zimmern has worked with prominent institutions that have further shaped his expertise. He has been associated with the Southwest Research Institute and the University of Pennsylvania, where he has contributed to pioneering research and development in bioprocessing and cellular therapies.
Collaborations
Zimmern has collaborated with notable colleagues, including Jian Ling and Michael C. Milone. These partnerships highlight the collaborative nature of research in the biotech field, which is often essential for the development of innovative solutions and technologies.
Conclusion
Kreg A. Zimmern’s work exemplifies the drive toward innovative solutions in bioprocessing technology. His patents not only advance T cell therapy for cancer treatment but also open avenues for wider applications in the field. As the healthcare landscape continually evolves, the contributions of inventors like Zimmern will remain crucial to improving treatments and outcomes for patients.